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Protein tyrosine phosphatase non-
receptor 22 and C-Src tyrosine 
kinase genes are down-regulated in 
patients with rheumatoid arthritis
Sara Remuzgo-Martínez1, Fernanda Genre1, Santos Castañeda2, Alfonso Corrales1, Pablo 
Moreno-Fresneda2, Begoña Ubilla1, Verónica Mijares1, Virginia Portilla1, Jesús González-Vela1, 
Trinitario Pina1, Gonzalo Ocejo-Vinyals3, Juan Irure-Ventura3, Ricardo Blanco1, Javier Martín4, 
Javier Llorca5, Raquel López-Mejías  1 & Miguel A. González-Gay1,6
Several protein tyrosine phosphatase non-receptor 22 (PTPN22) single-nucleotide polymorphisms (SNPs) 
have been significantly related with rheumatoid arthritis (RA) susceptibility. Nevertheless, its potential 
influence on PTPN22 expression in RA has not been completely elucidated. Furthermore, PTPN22 binds 
to C-Src tyrosine kinase (CSK) forming a key complex in autoimmunity. However, the information of CSK 
gene in RA is scarce. In this study, we analyzed the relative PTPN22 and CSK expression in peripheral 
blood from 89 RA patients and 43 controls to determine if the most relevant PTPN22 (rs2488457, 
rs2476601 and rs33996649) and CSK (rs34933034 and rs1378942) polymorphisms may influence on 
PTPN22 and CSK expression in RA. The association between PTPN22 and CSK expression in RA patients 
and their clinical characteristics was also evaluated. Our study shows for the first time a marked down-
regulation of PTPN22 expression in RA patients carrying the risk alleles of PTPN22 rs2488457 and 
rs2476601 compared to controls (p = 0.004 and p = 0.007, respectively). Furthermore, CSK expression 
was significantly lower in RA patients than in controls (p < 0.0001). Interestingly, a reduced PTPN22 
expression was disclosed in RA patients with ischemic heart disease (p = 0.009). The transcriptional 
suppression of this PTPN22/CSK complex may have a noteworthy clinical relevance in RA patients.
Mutations in the protein tyrosine phosphatase non-receptor 22 (PTPN22) gene are associated with numerous 
autoimmune diseases1, 2. In this regard, several PTPN22 single-nucleotide polymorphisms (SNPs) have been 
significantly related with susceptibility to rheumatoid arthritis (RA)3–7. Moreover, it has been suggested that 
PTPN22 modulation, at a transcriptional level, may influence on inflammatory processes associated with RA8, 9. 
In particular, the expression of a PTPN22 isoform was correlated with RA activity in whole peripheral blood 
from RA patients10. Accordingly, PTPN22 is considered as the main non-HLA genetic risk factor involved in RA 
pathogenesis11, and, in fact, PTPN22 expression profiles have been proposed as biomarkers of RA8–10. Despite 
these evidences, the influence of PTPN22 genetic variants on PTPN22 expression in RA has not been completely 
elucidated and contradictory results have been published. In this regard, whereas a study did not find any pol-
ymorphism associated with the expression of PTPN22 splice forms in peripheral blood cells of RA patients8, a 
possible trend for association between PTPN22 rs2488457 SNP and PTPN22 gene expression was described in 
RA patients from China12.
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Since PTPN22 is an intracellular tyrosine phosphatase that mainly inhibits T-cell receptor (TCR) signaling 
pathway, it is critically involved in the development of autoimmune diseases1, 2. This function is strengthened by 
the interaction with C-Src tyrosine kinase (CSK), also a negative regulator of TCR signaling13, 14. In this regard, 
two well-known CSK SNPs (rs34933034 and rs1378942) have been linked to systemic lupus erythematosus and 
systemic sclerosis15, 16. However, to the best of our knowledge, the information of CSK gene in RA is scarce.
A recent work from Walsh et al. reported some PTPN22 and CSK polymorphisms as potential expression 
quantitative trait loci (eQTLs) in whole blood from RA patients17 (information retrieved from additional files 
included in that manuscript). However, this study was not specially focused on the implication of PTPN22 and 
CSK in the pathogenesis of RA.
Taking all these considerations into account, in this study we determined if the most relevant PTPN22 
(rs2488457, rs2476601 and rs33996649) and CSK (rs34933034 and rs1378942) polymorphisms may influence 
on PTPN22 and CSK expression in whole peripheral blood of RA patients when compared to healthy controls. 
The association between PTPN22 and CSK expression in RA patients and their clinical characteristics was also 
studied.
Results
Influence of PTPN22 genetic variants on PTPN22 expression. In a first step, we compared the 
PTPN22 mRNA expression between healthy controls and patients with RA (4.66 ± 1.52 vs 4.07 ± 1.57, p = 0.04). 
However, these differences were not statistically significant after adjustment (p = 0.22) (Fig. 1a).
To determine if PTPN22 rs2488457, rs2476601 and rs33996649 polymorphisms may influence on PTPN22 
expression, we assessed the PTPN22 expression in RA patients and controls carrying the reference and the risk 
allele for each polymorphism (Table 1). After checking that PTPN22 rs2488457, rs2476601 and rs33996649 were 
in HWE, we observed a significant down-regulation of PTPN22 in patients with RA carrying PTPN22 rs2488457 
risk allele G and rs2476601 risk allele A compared to healthy controls (p = 0.004 and 0.007, respectively) (Fig. 2a,b 
and Table 1). A decreased PTPN22 mRNA expression was also disclosed between RA patients and healthy con-
trols carrying the haplotype GA, composed of both risk alleles (Supplementary Table 1). No statistical analy-
sis could be carried out to compare PTPN22 expression between patients and controls carrying the PTPN22 
rs33996649 polymorphism risk allele T, since only one control subject carried this allele (Table 1). According 
to individuals carrying the reference allele, no significant differences in PTPN22 mRNA expression were found 
between patients with RA and controls in any of the cases (Table 1).
Figure 1. Relative PTPN22 (a) and CSK (b) mRNA expression in healthy controls and patients with RA. 
PTPN22 and CSK expression was normalized to beta-actin and GAPDH as housekeeping genes. P-values were 
adjusted for sex, age, and cardiovascular risk factors. Horizontal bars indicate mean value of each study group. 
ns indicates not significant differences.
SNP Allele
Healthy controls 
n (%) n = 86
RA patients 
n (%) n = 174
PTPN22 mRNA expression controls 
vs RA patients (mean ± SD) P-value*
PTPN22 rs2488457
C 61 (70.9) 128 (73.6) 4.62 ± 1.55 vs 4.11 ± 1.60 0.89
G 25 (29.1) 46 (26.4) 4.78 ± 1.44 vs 3.95 ± 1.48 0.004
PTPN22 rs2476601
G 75 (87.2) 147 (84.5) 4.65 ± 1.57 vs 4.12 ± 1.62 0.47
A 11 (12.8) 27 (15.5) 4.76 ± 1.07 vs 3.80 ± 1.26 0.007
PTPN22 rs33996649
C 84 (97.7) 167 (96.0) 4.66 ± 1.53 vs 4.07 ± 1.56 0.09
T 2 (2.3) 7 (4.0) 4.74 ± 0.07 vs 4.03 ± 1.96 —
Table 1. Differential PTPN22 mRNA expression between healthy controls and RA patients according to their 
reference or risk allele for each PTPN22 SNP. RA: rheumatoid arthritis, SNP: single-nucleotide polymorphism, 
SD: standard deviation. Results in bold show statistically significant diffferences (p < 0.05). *P-values were 
adjusted by sex, age, and cardiovascular risk factors.
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Influence of CSK genetic variants on CSK expression. Firstly, we found a significant decrease in CSK 
mRNA expression in RA patients compared to controls (2.50 ± 0.77 vs 3.28 ± 1.02, p < 0.0001) (Fig. 1b). Then, we 
compared the CSK expression between these two study groups according to their reference and risk allele for CSK 
rs34933034 and rs1378942 (Table 2). Both polymorphisms were in HWE. We disclosed a decreased expression of CSK 
in patients with RA respect to controls, independently on whether they carried the CSK rs34933034 and rs1378942 
reference or risk allele (Fig. 2c,d and Table 2). This decrease in CSK expression was statistically significant in all the 
cases (p < 0.05), except for individuals who carried CSK rs34933034 risk allele A, that showed a marginally significant 
decrease (p = 0.059). Similar results were obtained when haplotype analysis was performed (Supplementary Table 1).
Association of PTPN22 and CSK mRNA expression with clinical characteristics in RA patients. 
Interestingly, a significant association between PTPN22 expression and ischemic heart disease (IHD) was 
observed in patients with RA, after and adjustment for sex, age at time of study, and CV risk factors (p = 0.009) 
(Fig. 3). In this regard, RA patients with IHD had a lower PTPN22 expression (3.02 ± 1.11) than those without 
Figure 2. Relative PTPN22 and CSK mRNA expression in healthy controls and patients with RA according to 
PTPN22 and CSK polymorphisms. PTPN22 and CSK expression was normalized to beta-actin and GAPDH as 
housekeeping genes. P-values were adjusted for sex, age, and cardiovascular risk factors. (a and b) Differential 
PTPN22 expression between controls and patients with RA stratified according to their reference and risk allele 
of PTPN22 rs2488457 (a) and PTPN22 rs2476601 (b) polymorphisms. (c and d) Differential CSK expression 
between controls and patients with RA stratified according to their reference and risk allele of CSK rs34933034 
(c) and CSK rs1378942 (d) polymorphisms. Horizontal bars indicate mean value of each study group.
SNP Allele
Healthy controls 
n (%) n = 86
RA patients n 
(%) n = 178
CSK mRNA expression controls 
vs RA patients (mean ± SD) P-value*
CSK rs34933034
G 64 (76.2) 138 (77.5) 3.33 ± 1.03 vs 2.45 ± 0.75 <0.0001
A 20 (23.8) 40 (22.5) 3.14 ± 1.01 vs 2.69 ± 0.79 0.059
CSK rs1378942
A 43 (50.0) 100 (56.2) 3.13 ± 0.93 vs 2.47 ± 0.74 <0.0001
C 43 (50.0) 78 (43.8) 3.44 ± 1.07 vs 2.55 ± 0.80 <0.0001
Table 2. Differential CSK mRNA expression between healthy controls and RA patients according to their 
reference or risk allele for each CSK SNP. RA: rheumatoid arthritis, SNP: single-nucleotide polymorphism, SD: 
standard deviation. Results in bold show statistically significant diffferences (p < 0.05). *P-values were adjusted 
by sex, age, and cardiovascular risk factors.
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IHD (4.32 ± 1.57) (Fig. 3). In addition, an inverse correlation was disclosed between CSK expression in patients 
with RA and their C-reactive protein (CRP) levels at time of study (r = −0.26, p = 0.019). No significant dif-
ferences were found between the PTPN22 and CSK mRNA expression of patients with RA and other clinical 
characteristics, including disease duration, rheumatoid factor, anti-cyclic citrullinated peptide antibodies status, 
erosions, extra-articular manifestations, and CRP levels and erythrocyte sedimentation rate at RA onset.
PTPN22 and CSK serum levels in RA and controls. The measurement of circulating levels of PTPN22 
and CSK was assessed to provide supplementary reliable data between the expression of mRNA and the corre-
sponding protein levels. No significant differences were found between patients with RA and controls in PTPN22 
and CSK protein levels after adjustment by potential confounding factors. In this regard, PTPN22 levels were 
450.59 ± 328.76 pg/ml in RA patients and 285.80 ± 259.70 pg/ml in controls (p = 0.20). Similarly, CSK levels were 
39.02 ± 26.10 pg/ml in RA patients and 32.35 ± 24.53 in controls (p = 0.76).
Discussion
Since an association between some PTPN22 genetic variants and RA susceptibility was described3–7, functional 
analyses of PTPN22 have been considered necessary to further understand the role of this gene in RA and other 
autoimmune diseases1, 9. Our study disclosed for the first time that two PTPN22 genetic variants, rs2488457, 
located in the promoter region, and rs2476601, located in exon 14, down-regulate the transcription and function of 
PTPN22 in patients with RA compared to controls, who have higher PTPN22 expression. This was observed both 
when the PTPN22 SNPs were analyzed individually or forming haplotypes. Our results confirm the trend found 
between PTPN22 rs2488457 and PTPN22 expression in Chinese RA patients12. Furthermore, Zhang et al. had 
previously shown that this SNP was associated not only with the development of an inflammatory disease known 
as Vogt-Koyanagi-Harada, but also with a decreased PTPN22 expression, only assessed in healthy controls18. A 
potential influence between rs2488457 and ulcerative colitis was also described19. Regarding PTPN22 rs2476601, 
it has been clearly shown that it is the main variant involved in the susceptibility to develop autoimmune dis-
eases1–3, and due to its functional effect it is able to decrease the interaction between PTPN22 and CSK14, 20. 
No association between this SNP and PTPN22 modulation had previously been shown8, 21, 22. However, PTPN22 
rs2476601 and also PTPN22 rs2488457 have been recently proposed as potential cis-eQTLs in whole blood from 
RA patients17. This finding is in keeping with our results, supporting that these genetic variants may play an 
important role in the regulatory region of PTPN22. Based on our data, we feel that the decreased PTPN22 expres-
sion in patients carrying the risk alleles of PTPN22 rs2488457 and rs2476601 may lead to a pro-inflammatory 
status in RA, since T cells activation would not be inhibited by this gene. In fact, PTPN22 deficiency significantly 
increased the severity of disease in a mouse model of RA23.
An important implication of PTPN22 in the development of atherosclerosis has previously been proposed24. 
In this regard, we disclosed for the first time a marked down-regulation of PTPN22 gene in RA patients with IHD. 
Considering a previous study from our group which showed that PTPN22 rs2476601 polymorphism was not 
directly associated with an increased risk of CV disease in RA patients25, we think that this association may be 
SNP-independent and could constitute an useful tool to identify RA patients with a higher CV risk.
We also demonstrated a significant decrease of CSK gene in peripheral blood from RA patients. A 
down-regulation of CSK, which acts as a tumor suppressor gene, has previously been associated with colon cancer26. 
However, the role of CSK gene in RA remains to be elucidated, even though it has been proposed as an auto-
immunity risk factor16. Since a study demonstrated a decrease of inflammation in a rat model of RA injected 
with Csk virus27, we consider that the down-regulation of CSK may cause a high inflammatory response in our 
Figure 3. Decrease PTPN22 mRNA expression in RA patients with IHD. Box plot showing the PTPN22 mRNA 
expression, normalized to beta-actin and GAPDH expression, in patients with rheumatoid arthritis (RA) 
stratified according to the presence (n = 16) or absence of ischemic heart disease (IHD) (n = 71). P-value was 
adjusted for sex, age, and cardiovascular risk factors.
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patients, contributing to RA progression. Finally, we observed that CSK rs34933034 and rs1378942 did not influ-
ence on CSK expression since its reduction in RA patients as compared to controls was independent of the pol-
ymorphisms. Therefore, the lower CSK mRNA expression shown in our RA patients when compared to healthy 
controls may be more related to the disease itself. The negative association of CSK mRNA expression with CRP, a 
systemic marker of inflammation, reinforces our hypothesis.
In summary, our study reveals for the first time that the risk alleles of PTPN22 rs2488457 and PTPN22 
rs2476601 influence on the down-regulation of PTPN22 in RA. This confirms the important role of PTPN22 in 
RA. Furthermore, it indicates that CSK may also be considered as a genetic risk factor for the development of 
RA. The transcriptional suppression of the PTPN22/CSK complex, as a key regulator of the immune response, 
may have a noteworthy clinical relevance in patients with RA, playing an important role in disease progression. 
Compensatory mechanisms through other biologic pathways may be crucial to control RA.
Subjects and Methods
Patients and controls. For experiments involving humans and the use of human blood samples, all 
the methods were carried out in accordance with the approved guidelines and regulations, according to 
the Declaration of Helsinki. All experimental protocols were approved by the local Ethics Committees of 
Clinical research of Cantabria for Hospital Universitario Marqués de Valdecilla in Santander and of Madrid 
for Hospital Universitario de La Princesa. An informed consent was obtained from all subjects before being 
enrolled.
Peripheral blood samples were collected from 89 patients with RA who met the 1987 American College of 
Rheumatology (ACR) and also the 2010 ACR/European League Against Rheumatism criteria for RA28, 29 and 43 
healthy controls recruited from Hospital Universitario Marqués de Valdecilla (Santander, Spain) and Hospital 
Universitario de La Princesa (Madrid, Spain). Supplementary Table 2 shows the main demographic and clinical 
characteristics of subjects enrolled in this study.
Expression profiles of PTPN22 and CSK genes. Total RNA from peripheral blood was isolated using 
NucleoSpin RNA Blood Midi kit (Macherey-Nagel) according to the manufacturer’s protocol, as we previously 
described30, 31. 1 μg of total RNA was reverse-transcribed using iScriptTM Advanced cDNA Synthesis Kit for 
RT- qPCR (Bio-Rad, Hercules, CA, USA). 20 ng of cDNA was used for quantitative real-time PCR (qPCR), using 
SsoAdvancedTM Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA). Primers for amplification 
of PTPN22 (135 bp, UniGene ID Hs.535276), CSK (73 bp, UniGene ID Hs.77793), beta-actin (62 bp, UniGene 
ID Hs.520640) and GAPDH (117 bp, UniGene ID Hs. 544577) genes were acquired from PrimePCR Assays, 
Bio-Rad, Hercules, CA, USA. All samples were examined in triplicate and controls were included in each reac-
tion. qPCRs were performed in a 7900 HT real-time instrument (Applied Biosystems, Foster City, CA, USA) 
following the conditions previously reported31. Amplicons of the different genes and a 50 base pairs DNA lad-
der (ThermoScientific) were electrophoresed on 2% agarose gel stained with GelGreen Nucleic Acid Gel stain 
(Biotium) to check the appropriate size of each amplicon (Supplementary Figure 1). CSK gene was expressed 
successfully in all samples. However, PTPN22 was not detected in 2 out of the 89 patients enrolled. The relative 
PTPN22 and CSK mRNA (messenger RNA) expression was analyzed by the comparative threshold cycle method, 
using beta-actin and GAPDH as housekeeping genes30. Normalized values were obtained for each sample and 
mean values were determined for each study group.
PTPN22 and CSK genotyping. Genomic DNA was extracted from peripheral blood samples using 
NucleoSpin Blood Kit (Macherey-Nagel) according to the manufacturer’s recommendations. Genotyping of the 
PTPN22 rs2488457 (C > G), PTPN22 rs2476601 (G > A), PTPN22 rs33996649 (C > T), CSK 34933034 (G > A) 
and CSK rs1378942 (A > C) was performed using TaqMan probes in a 7900 HT real-time instrument (Applied 
Biosystems, Foster City, CA, USA), as previously reported32. Negative controls were included to check the accu-
racy of genotyping. The linkage disequilibrium pattern of the PTPN22 and CSK polymorphisms is displayed in 
Supplementary Figure 2.
PTPN22 and CSK serum levels by enzyme-linked immunosorbent assay (ELISA). PTPN22 
and CSK serum levels were determined using commercial kits acquired from CUSABIO (Catalog Number: 
CSB-EL019036HU and CSB-EL006056HU, respectively), according to the manufacturer’s instructions. All sam-
ples were analyzed in duplicate.
Statistical analysis. First, Student’s t test was used to compare differences in PTPN22 and CSK mRNA 
expression between: patients and controls, patients and controls stratified according to their reference or 
risk allele for each SNP, as well as patients and controls stratified according to PTPN22 and CSK haplotypes. 
Differences in PTPN22 and CSK serum levels between RA patients and controls were also assessed by Student’s 
t test. Results were expressed as mean ± standard deviation for each study group. Next, covariance analysis was 
performed in order to adjust the results by potential confounding factors, including sex, age at time of study, and 
cardiovascular (CV) risk factors (hypertension, dyslipidemia, smoking, diabetes and obesity)33. The association 
between PTPN22 and CSK mRNA expression in RA patients and their clinical characteristics was evaluated using 
Student’s t test or Pearson partial correlation coefficients (r) as required, after adjusting for the confounding 
factors commented above. In all cases, p-values < 0.05 were considered statistically significant. Regarding gen-
otyping, Hardy-Weinberg equilibrium (HWE) was checked using Χ2 test. The statistical power of the study is 
displayed in Supplementary Table 3. All these analysis were performed with STATA statistical software 12.0 (Stata 
Corp., College Station, TX, USA).
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